BMRN Stock Analysis: Biomarin Pharmaceutical | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 11.402m USD | 12M Return: 2.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 114M
EPS Trend: 85.7%
Qual. Beats: 0
Rev. Trend: 99.2%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BioMarin Pharmaceutical Inc. (BMRN) is a U.S.-based biotechnology company founded in 1996 and headquartered in San Rafael, California, that develops and commercializes therapies for life-threatening rare diseases and medical conditions. It markets several specialty treatments, including VIMIZIM (MPS IV type A), VOXZOGO (achondroplasia), NAGLAZYME (MPS VI), PALYNZIQ (phenylketonuria), BRINEURA (Batten disease), ALDURAZYME, and KUVAN. Its pipeline includes BMN 333 for growth disorders and BMN 351 for Duchenne muscular dystrophy. The company sells globally-across the U.S., Europe, Latin America, the Middle East, and Asia Pacific-through specialty pharmacies, hospitals, government agencies, distributors, and pharmaceutical wholesalers, and holds a license and collaboration agreement with Ares Trading S.A.
As a large-cap biotechnology company listed on NASDAQ since 1999, BioMarin operates within the orphan drug business model, focusing on treatments for small patient populations with limited therapeutic alternatives. This specialization typically allows for extended market exclusivity under orphan drug designations, though it also concentrates revenue among a small number of high-cost specialty therapies.
- VOXZOGO drives top-line growth as achondroplasia launch expands globally
- PALYNZIQ revenue climbs with broader PKU patient uptake and label expansion
- Pipeline catalysts from BMN 333 and BMN 351 shape long-term growth narrative
| Net Income: 268.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.25 > 1.0 |
| NWC/Revenue: 117.6% < 20% (prev 96.25%; Δ 21.31% < -1%) |
| CFO/TA 0.10 > 3% & CFO 874.3m > Net Income 268.7m |
| Net Debt (-773.5m) to EBITDA (482.5m): -1.60 < 3 |
| Current Ratio: 5.81 > 1.5 & < 3 |
| Outstanding Shares: last quarter (197.7m) vs 12m ago 0.61% < -2% |
| Gross Margin: 75.93% > 18% (prev 79.44%; Δ -3.50% > 0.5%) |
| Asset Turnover: 41.20% > 50% (prev 41.28%; Δ -0.08% > 0%) |
| Interest Coverage Ratio: 17.77 > 6 (EBIT TTM 408.6m / Interest Expense TTM 23.0m) |
| A: 0.44 (Total Current Assets 4.61b - Total Current Liabilities 793.2m) / Total Assets 8.59b |
| B: 0.03 (Retained Earnings 259.7m / Total Assets 8.59b) |
| C: 0.05 (EBIT TTM 408.6m / Avg Total Assets 7.87b) |
| D: 2.61 (Book Value of Equity 6.21b / Total Liabilities 2.38b) |
| Altman-Z'' = 6.10 = AAA |
| DSRI: 1.11 (Receivables 903.9m/739.2m, Revenue 3.24b/2.95b) |
| GMI: 1.05 (GM 79.44% / 75.93%) |
| AQI: 0.95 (AQ_t 0.35 / AQ_t-1 0.37) |
| SGI: 1.10 (Revenue 3.24b / 2.95b) |
| TATA: -0.07 (NI 268.7m - CFO 874.3m) / TA 8.59b) |
| Beneish M = -2.86 (Cap -4..+1) = A |
As of July 06, 2026, the stock is trading at USD 58.99 with a total of 1,483,600 shares traded. Over the past week, the price has changed by +2.86%, over one month by +3.91%, over three months by +4.95% and over the past year by +2.75%.
Current recommended Stop Loss: 56.00 (which is 5.1% or 1.8 ATR below the current price).
Biomarin Pharmaceutical has received a consensus analysts rating of 4.34. Therefore, it is recommended to buy BMRN.
- StrongBuy: 16
- Buy: 7
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 87.9 | 48.9% |
P/E Trailing = 42.4389
P/E Forward = 11.8483
P/S = 3.5166
P/B = 1.8357
P/EG = 0.7251
Revenue TTM = 3.24b USD
EBIT TTM = 408.6m USD
EBITDA TTM = 482.5m USD
Long Term Debt = 1.43b USD (from longTermDebt, last quarter)
Short Term Debt = 9.32m USD (from shortTermDebt, last quarter)
Debt = 1.45b USD (from shortLongTermDebtTotal, last quarter) + Leases 9.32m
Net Debt = -773.5m USD (calculated: Debt 1.45b - CCE 2.22b)
Enterprise Value = 10.6b USD (11.4b + Debt 1.45b - CCE 2.22b)
Interest Coverage Ratio = 17.77 (Ebit TTM 408.6m / Interest Expense TTM 23.0m)
EV/FCF = 13.86x (Enterprise Value 10.6b / FCF TTM 767.1m)
FCF Yield = 7.22% (FCF TTM 767.1m / Enterprise Value 10.6b)
FCF Margin = 23.66% (FCF TTM 767.1m / Revenue TTM 3.24b)
Net Margin = 8.29% (Net Income TTM 268.7m / Revenue TTM 3.24b)
Gross Margin = 75.93% ((Revenue TTM 3.24b - Cost of Revenue TTM 780.3m) / Revenue TTM)
Gross Margin QoQ = 74.55% (prev 66.26%)
Tobins Q-Ratio = 1.24 (Enterprise Value 10.6b / Total Assets 8.59b)
Interest Expense / Debt = 1.59% (Interest Expense 23.0m / Debt 1.45b)
Taxrate = 30.30% (116.9m / 385.6m)
NOPAT = 284.8m (EBIT 408.6m * (1 - 30.30%))
Current Ratio = 5.81 (Total Current Assets 4.61b / Total Current Liabilities 793.2m)
Debt / Equity = 0.23 (Debt 1.45b / totalStockholderEquity, last quarter 6.21b)
Debt / EBITDA = -1.60 (Net Debt -773.5m / EBITDA 482.5m)
Debt / FCF = -1.01 (Net Debt -773.5m / FCF TTM 767.1m)
Total Stockholder Equity = 6.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.42% (Net Income 268.7m / Total Assets 8.59b)
RoE = 4.41% (Net Income TTM 268.7m / Total Stockholder Equity 6.10b)
RoCE = 5.43% (EBIT 408.6m / Capital Employed (Equity 6.10b + L.T.Debt 1.43b))
RoIC = 3.72% (NOPAT 284.8m / Invested Capital 7.65b)
WACC = 6.56% (E(11.4b)/V(12.9b) * Re(7.25%) + D(1.45b)/V(12.9b) * Rd(1.59%) * (1-Tc(0.30)))
Discount Rate = 7.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 2.22 | Cagr: 1.34%
[DCF] Terminal Value 77.97% ; FCFF base≈708.3m ; Y1≈812.0m ; Y5≈1.19b
[DCF] Fair Price = 97.04 (EV 18.0b - Net Debt -773.5m = Equity 18.8b / Shares 193.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 85.71 | EPS CAGR: 37.12% | SUE: -0.57 | # QB: 0
Revenue Correlation: 99.19 | Revenue CAGR: 15.51% | SUE: 0.56 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.96 | Chg30d=+0.14% | Revisions=+0% | Analysts=15
EPS next Quarter (2026-09-30): EPS=1.49 | Chg30d=+0.13% | Revisions=+36% | Analysts=15
EPS current Year (2026-12-31): EPS=4.94 | Chg30d=+0.05% | Revisions=-8% | GrowthEPS=+56.8% | GrowthRev=+21.0%
EPS next Year (2027-12-31): EPS=6.46 | Chg30d=-0.13% | Revisions=-30% | GrowthEPS=+30.7% | GrowthRev=+14.5%
[Analyst] Revisions Ratio: +0% (up=14, down=14)